Valneva SE

VALN

8.650USD

-0.190-2.15%

Close 09/05, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

128 / 686

Overall Ranking

219 / 4731

Industry

Pharmaceuticals & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

13.675

Target Price

+54.69%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Fairly Valued

The company’s latest is -18.80, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 665.50K shares, decreasing 31.13% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 3.26.

The company's current financial score is 7.83, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 49.23M, representing a year-over-year increase of 50.31%, while its net profit experienced a year-over-year increase of 115.67%.

Score

Industry at a Glance

Previous score

7.83

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.46

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.44

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.15

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is -19.02, which is -41.74% below the recent high of -11.08 and -72.04% above the recent low of -32.73.

Score

Industry at a Glance

Previous score

1.20

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 128/686

No Data

The company’s current earnings forecast score is 8.50, which is higher than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for Valneva SE is 14.00, with a high of 18.00 and a low of 8.70.

Score

Industry at a Glance

Previous score

8.50

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 7.12, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 11.62 and the support level at 6.52, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.85

Change

-0.09

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-05

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

General American Investors Company, Inc.

354.36K

--

Wells Fargo Advisors

243.22K

-1.44%

Citadel Advisors LLC

27.22K

-60.83%

Ironwood Investment Management, LLC

25.02K

--

Morgan Stanley & Co. International Plc

3.73K

+149.00%

VSM Wealth Advisory, LLC

4.00K

+300.00%

Geode Capital Management, L.L.C.

2.88K

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 3.49, which is lower than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is 1.79. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Valneva SE

VALN

5.91 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.64 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

7.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Stoke Therapeutics Inc

STOK

7.52 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

7.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.